These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23665912)

  • 1. O-GlcNAcylation involvement in high glucose-induced cardiac hypertrophy via ERK1/2 and cyclin D2.
    Ding F; Yu L; Wang M; Xu S; Xia Q; Fu G
    Amino Acids; 2013 Aug; 45(2):339-49. PubMed ID: 23665912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy.
    Yokoe S; Asahi M; Takeda T; Otsu K; Taniguchi N; Miyoshi E; Suzuki K
    Glycobiology; 2010 Oct; 20(10):1217-26. PubMed ID: 20484118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation.
    Clark RJ; McDonough PM; Swanson E; Trost SU; Suzuki M; Fukuda M; Dillmann WH
    J Biol Chem; 2003 Nov; 278(45):44230-7. PubMed ID: 12941958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O-linked β-N-acetylglucosamine supports p38 MAPK activation by high glucose in glomerular mesangial cells.
    Goldberg H; Whiteside C; Fantus IG
    Am J Physiol Endocrinol Metab; 2011 Oct; 301(4):E713-26. PubMed ID: 21712532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting O-GlcNAcylation impacts p38 and Erk1/2 signaling and perturbs cardiomyocyte hypertrophy.
    Papanicolaou KN; Jung J; Ashok D; Zhang W; Modaressanavi A; Avila E; Foster DB; Zachara NE; O'Rourke B
    J Biol Chem; 2023 Mar; 299(3):102907. PubMed ID: 36642184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyper-O-GlcNAcylation inhibits the induction of heat shock protein 70 (Hsp 70) by sodium arsenite in HeLa cells.
    Miura Y; Sato T; Sakurai Y; Sakai R; Hiraoka W; Endo T
    Biol Pharm Bull; 2014; 37(8):1308-14. PubMed ID: 25087952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation.
    Gélinas R; Mailleux F; Dontaine J; Bultot L; Demeulder B; Ginion A; Daskalopoulos EP; Esfahani H; Dubois-Deruy E; Lauzier B; Gauthier C; Olson AK; Bouchard B; Des Rosiers C; Viollet B; Sakamoto K; Balligand JL; Vanoverschelde JL; Beauloye C; Horman S; Bertrand L
    Nat Commun; 2018 Jan; 9(1):374. PubMed ID: 29371602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in left ventricular function during intermittent hypoxia: Possible involvement of O-GlcNAc protein and MAPK signaling.
    Guo X; Shang J; Deng Y; Yuan X; Zhu D; Liu H
    Int J Mol Med; 2015 Jul; 36(1):150-8. PubMed ID: 25936416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of the O-GlcNAc modification in the regulation of nuclear apoptosis in T cells.
    Johnson B; Opimba M; Bernier J
    Biochim Biophys Acta; 2014 Jan; 1840(1):191-8. PubMed ID: 24035784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperglycemia suppresses cardiac stem cell homing to peri-infarcted myocardium via regulation of ERK1/2 and p38 MAPK activities.
    She T; Wang X; Gan Y; Kuang D; Yue J; Ni J; Zhao X; Wang G
    Int J Mol Med; 2012 Dec; 30(6):1313-20. PubMed ID: 22965067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart.
    Prakoso D; Lim SY; Erickson JR; Wallace RS; Lees JG; Tate M; Kiriazis H; Donner DG; Henstridge DC; Davey JR; Qian H; Deo M; Parry LJ; Davidoff AJ; Gregorevic P; Chatham JC; De Blasio MJ; Ritchie RH
    Cardiovasc Res; 2022 Jan; 118(1):212-225. PubMed ID: 33576380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Swim-exercised mice show a decreased level of protein O-GlcNAcylation and expression of O-GlcNAc transferase in heart.
    Belke DD
    J Appl Physiol (1985); 2011 Jul; 111(1):157-62. PubMed ID: 21493720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excessive O-GlcNAcylation of proteins suppresses spontaneous cardiogenesis in ES cells.
    Kim HS; Park SY; Choi YR; Kang JG; Joo HJ; Moon WK; Cho JW
    FEBS Lett; 2009 Aug; 583(15):2474-8. PubMed ID: 19591829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure.
    Lunde IG; Aronsen JM; Kvaløy H; Qvigstad E; Sjaastad I; Tønnessen T; Christensen G; Grønning-Wang LM; Carlson CR
    Physiol Genomics; 2012 Feb; 44(2):162-72. PubMed ID: 22128088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased O-GlcNAcylation induces myocardial hypertrophy.
    Chen X; Zhang L; He H; Sun Y; Shen Q; Shi L
    In Vitro Cell Dev Biol Anim; 2020 Oct; 56(9):735-743. PubMed ID: 32996013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy.
    Huang S; Zou X; Zhu JN; Fu YH; Lin QX; Liang YY; Deng CY; Kuang SJ; Zhang MZ; Liao YL; Zheng XL; Yu XY; Shan ZX
    J Cell Mol Med; 2015 Mar; 19(3):608-19. PubMed ID: 25583328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.
    Zhang X; Ma L; Qi J; Shan H; Yu W; Gu Y
    Mol Cell Biochem; 2015 Dec; 410(1-2):101-10. PubMed ID: 26318312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes.
    Li SY; Sigmon VK; Babcock SA; Ren J
    Life Sci; 2007 Feb; 80(11):1051-6. PubMed ID: 17174344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmented TME
    Moriwaki K; Asahi M
    Mol Cancer Res; 2017 Sep; 15(9):1287-1298. PubMed ID: 28536142
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained Increases in Cardiomyocyte Protein
    Ha CM; Bakshi S; Brahma MK; Potter LA; Chang SF; Sun Z; Benavides GA; He L; Umbarkar P; Zou L; Curfman S; Sunny S; Paterson AJ; Rajasekaran NS; Barnes JW; Zhang J; Lal H; Xie M; Darley-Usmar VM; Chatham JC; Wende AR
    J Am Heart Assoc; 2023 Oct; 12(19):e029898. PubMed ID: 37750556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.